Stay updated on Empagliflozin Effects on Diastolic Function in Diabetics Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin Effects on Diastolic Function in Diabetics Clinical Trial page.

Latest updates to the Empagliflozin Effects on Diastolic Function in Diabetics Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new collaborators, specifically Boehringer Ingelheim, and a new version revision number. Additionally, the specific study identifier (EudraCT Number) has been added, while significant content regarding the purpose and details of the EmDia trial has been removed.SummaryDifference35%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Empagliflozin Effects on Diastolic Function in Diabetics Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin Effects on Diastolic Function in Diabetics Clinical Trial page.